

Resource Summary Report

Generated by [kravitz2](#) on Aug 19, 2026

PE/Fire(TM) 700 anti-mouse CD3

RRID:AB_2876394

Type: Antibody

Proper Citation

BioLegend Cat# 100271, RRID:AB_2876394

Antibody Information

URL: http://antibodyregistry.org/AB_2876394

Proper Citation: BioLegend Cat# 100271, RRID:AB_2876394

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE/Fire(TM) 700 anti-mouse CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Antibody ID: AB_2876394

Vendor: BioLegend

Catalog Number: 100271

Alternative Catalog Numbers: 100272

Record Creation Time: 20250819T213944+0000

Record Last Update: 20250819T234118+0000

Ratings and Alerts

No rating or validation information has been found for PE/Fire(TM) 700 anti-mouse CD3.

No alerts have been found for PE/Fire(TM) 700 anti-mouse CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Bosma DMT, et al. (2026) Requirements for development of T helper 1 and T follicular helper cells from a common precursor. Cell reports, 45(5), 117296.

Gujar R, et al. (2025) Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells. Cell reports. Medicine, 6(11), 102446.

Newsome RC, et al. (2025) Microbial-derived immunostimulatory small molecule augments anti-PD-1 therapy in lung cancer. Cell reports. Medicine, 102519.

Wienke J, et al. (2024) Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy. Cancer cell, 42(2), 283.

van der Sluis TC, et al. (2023) OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T??cell differentiation spectrum. Cell reports. Medicine, 4(3), 100939.